This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| LaMSID | |
|---|---|
| Name | LaMSID |
| Type | Biophysical actuator |
| Developer | Multidisciplinary consortium |
| Introduced | 21st century |
| Applications | Molecular sensing, nanorobotics, therapeutics |
LaMSID LaMSID is a modular light-activated molecular switch and injector device used in nanoscale manipulation. It integrates photoresponsive domains, engineered delivery modules, and programmable control elements to enable targeted actuation in cellular, synthetic, and materials contexts.
LaMSID was developed through collaborations among institutions such as Massachusetts Institute of Technology, Stanford University, Harvard University, California Institute of Technology, ETH Zurich, Imperial College London, University of Cambridge, University of Oxford, Max Planck Society, Karolinska Institutet, Riken, National Institutes of Health, NASA, European Space Agency, Wellcome Trust, Howard Hughes Medical Institute, Fraunhofer Society, Lawrence Berkeley National Laboratory, Los Alamos National Laboratory, Oak Ridge National Laboratory, Argonne National Laboratory, The Scripps Research Institute, Johns Hopkins University, University of California, San Francisco, University of Tokyo, Seoul National University, Tsinghua University, Peking University, University of Toronto, McGill University, University of British Columbia, University of Melbourne, University of Sydney, Monash University, University of Queensland, National University of Singapore, Nanyang Technological University, Duke University, Princeton University, Yale University, Columbia University, University of Chicago, Brown University, Cornell University, Northwestern University, University of Pennsylvania, Rice University, Texas A&M University, University of Texas at Austin] in response to demand for precise nanoscale delivery, drawing on techniques refined in fields represented by Nobel Prize-winning research and by technologies used at facilities like CERN and SLAC National Accelerator Laboratory.
LaMSID combines a photoreceptor core with mechanical transducer modules and cargo-binding domains. The photoreceptor core often adapts chromophores characterized in studies at Max Planck Institute of Biophysics, Riken Center for Emergent Matter Science, Lawrence Livermore National Laboratory, Kavli Institute for Theoretical Physics, and laboratories led by laureates such as Roger Tsien, Osamu Shimomura, Martin Chalfie, W. E. Moerner, Stefan Hell, Eric Betzig, Emmanuelle Charpentier, Jennifer Doudna, Frances Arnold, George Smith, and Craig Venter. Mechanical transducers incorporate protein scaffolds and synthetic polymers from work influenced by groups at IBM Research, Microsoft Research, Google DeepMind, Bell Labs, AT&T Labs Research, Nokia Bell Labs, and startups incubated at Y Combinator and Wellcome Trust Sanger Institute. Cargo-binding domains derive from engineered modules reported by research teams at Genentech, Amgen, Pfizer, Novartis, Roche, GlaxoSmithKline, AstraZeneca, Bayer, Sanofi, Eli Lilly and Company, and academic labs at Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center.
LaMSID operates through photon absorption leading to conformational change, coupling light excitation to mechanical work. This mechanism builds on photophysics characterized in classic experiments at Bell Laboratories, Rutherford Appleton Laboratory, Brookhaven National Laboratory, National Renewable Energy Laboratory, and theories advanced by researchers associated with Marie Curie, Max Planck, Albert Einstein, Niels Bohr, Werner Heisenberg, Paul Dirac, Erwin Schrödinger, Linus Pauling, and contemporary groups at Harvard Medical School, MIT Media Lab, Oxford Nanopore Technologies, Cold Spring Harbor Laboratory, Salk Institute, Weizmann Institute of Science, and Broad Institute. Photon-driven transitions trigger actuator segments analogous to mechanisms used in research by Feynman-inspired nanotechnology programs and mimic molecular machines described by teams from European Molecular Biology Laboratory, Center for Nanotechnology Innovation, Centre National de la Recherche Scientifique, Institut Pasteur, CNRS, Institut Curie, Tokyo Institute of Technology, and Tohoku University.
LaMSID enables intracellular delivery, extracellular matrix remodeling, nanopatterning, and precision catalysis. Demonstrations have been reported in studies connected to National Institutes of Health-funded initiatives, translational programs at Clinical Center (NIH), tissue engineering at Wyss Institute for Biologically Inspired Engineering, gene therapy research at CRISPR Therapeutics, immunotherapy efforts at CAR-T research centers, materials science projects at Argonne National Laboratory, Brookhaven National Laboratory, and space biology experiments coordinated with NASA Ames Research Center, European Space Agency technology transfer units, and industrial collaborations with BASF, Dow Chemical Company, 3M, Siemens, Schneider Electric, Bosch, Hitachi, Toyota Research Institute, Honda Research Institute, and Samsung Research.
Performance metrics for LaMSID are benchmarked against optical actuators, molecular motors, and nanomachine prototypes developed in laboratories at Stanford Nanofabrication Facility, MIT.nano, UCSF Nanolab, Zymtronix, National Microbiology Laboratory (Canada), Sandia National Laboratories, Pacific Northwest National Laboratory, Argonne National Laboratory, Los Alamos National Laboratory, and industry standards influenced by reports from ISO, IEEE, American Chemical Society, Royal Society of Chemistry, Nature Publishing Group, Science (journal), Cell Press, PNAS, ACS Nano, Nano Letters, and Advanced Materials. Efficiency depends on photon flux, chromophore quantum yield, and mechanical coupling similar to parameters optimized in work by teams led by Ada Yonath, Venki Ramakrishnan, Thomas A. Steitz, Ada E. Yonath, and structural biology groups at Diamond Light Source and European Synchrotron Radiation Facility.
LaMSID evolved from foundational studies in photochemistry, protein engineering, and nanomechanics conducted in institutions including Royal Institution, Royal Society, Howard Hughes Medical Institute, Wellcome Trust, Bill & Melinda Gates Foundation-supported programs, and national labs such as Argonne National Laboratory and Lawrence Berkeley National Laboratory. Key conceptual milestones trace to trials by pioneers like James Watson, Francis Crick, Rosalind Franklin, Linus Pauling, Kary Mullis, Herbert Boyer, Stanley Cohen, and engineering efforts influenced by Isambard Kingdom Brunel-era mechanical design principles as adapted by contemporary innovators at Tesla, Inc., SpaceX, Blue Origin, and academic spinouts from University of California, Berkeley and California Institute of Technology.
Safety assessments follow protocols adapted from standards at Food and Drug Administration, European Medicines Agency, National Institutes of Health, Occupational Safety and Health Administration, World Health Organization, International Agency for Research on Cancer, Environmental Protection Agency, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and institutional review boards at Johns Hopkins University, Mayo Clinic, Cleveland Clinic, UCLA Health, and Mount Sinai Health System. Limitations include phototoxicity, off-target interactions, delivery constraints, and regulatory hurdles flagged in reviews published by Nature Reviews Drug Discovery, Science Translational Medicine, The Lancet, BMJ, and policy analyses from OECD and World Bank.
Category:Biophysical devices